Logo - springer
Slogan - springer

Medicine - Internal Medicine | 30th Hemophilia Symposium Hamburg 1999 - HIV Infection and Epidemiology in Hemophilia; Gene Therapy

30th Hemophilia Symposium Hamburg 1999

HIV Infection and Epidemiology in Hemophilia; Gene Therapy in Hemophilia A and B; Therapy of Hepatitis C; Inhibitors in Hemophilia; Long-term Results after Joint Replacement; Pediatric Hemostasiology; Case Reports

Scharrer, I., Schramm, W. (Eds.)

2001, XXXIV, 428 p. 58 illus., 1 illus. in color.

Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$69.99

(net) price for USA

ISBN 978-3-642-18240-2

digitally watermarked, no DRM

Included Format: PDF

download immediately after purchase


learn more about Springer eBooks

add to marked items

Softcover
Information

Softcover (also known as softback) version.

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$99.00

(net) price for USA

ISBN 978-3-540-67677-5

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

This book contains the contributions to the 30th Hemophilia Symposium, 1999. The main topics are HIV infection, inhibitors in hemophilia, modern treatment of hemophilia, drug-induced thrombophilia and pediatric hemostasiology. The volume is rounded off by numerous free papers and posters on hemophilia and associated topics.

Content Level » Research

Keywords » HIV - HIV infection - epidemiology - gene therapy - hemophilia - hepatitis C infection - infection - pediatric hemostaseology - v. Willebrand's disease

Related subjects » Anesthesiology - Internal Medicine - Pediatrics

Table of contents 

I. HIV Infection and Epidemiology in Hemophilia.- Causes of Death and AIDS-Related Disease of Hemophilia Patients in Germany (Inquiries 1999).- II. Gene Therapy in Hemophilia.- Genotype—Phenotype Correlation in Hemophilia A.- III. Therapy of Hepatitis C.- Current Therapy of Hepatitis C Virus Infection.- Interferon Alpha-2a Treatment in Patients with Hepatitis C and Bleeding Disorders.- Report on Experience in the Treatment of Hepatitis C in HIV-Coinfected Hemophiliacs.- IV. Inhibitors in Hemophilia.- A New Therapeutic Option for Inhibitor Elimination in Patients with Acquired Hemophilia.- V. Long-Term Results After Joint Replacement.- Long-Term Results After Total Knee and Total Hip Replacement in Hemophilie Arthropathy.- Total Knee Prosthesis in Hemophiliacs with Multilocular Hemophilie Arthropathy—The Zurich Experience.- Corrective Osteotomy of the Lower Extremity in Hemophilie Arthropathy of the Knee and Hip Joint.- VI. Pediatrie Hemostasiology.- Anticoagulant Action of Activated Protein C is Diminished by Alpha2-Macroglobulin in Newborn Plasma.- Functional Consequences of Differences in Carbohydrate Sequences of Fetal and Adult Plasminogen and Fibrinogen.- Hereditary Thrombophilic Risk Profiles in Children with Spontaneous Venous Thromboembolism.- Inhibitor Development in Previously Untreated Patients with Hemophilia A and B: A Prospective 23-Year Follow-Up.- HIT Type II without Thrombocytopenia in a 15-Year-Old Boy with Protein S Deficiency and Recurrent Deep Vein Thrombosis.- VII. Free Lectures.- Modified Bonn-Malmö Protocol.- A Novel Type of Mutation at the Propeptide Cleavage Site (Ala+lThr) Causing Symptomatic Protein C Type II Deficiency.- Lithuanian Hemophilia A and B Register Comprising Phenotypic and Genotypic Data.- Greifswald Hemophilia B Study.- Successful Treatment of Patients with von Willebrand Disease Using a High-Purity Double Virus Inactivated FVIII/vWF Concentrate (IMMUNATE).- VIII. Research Cooperation.- Industry Sponsoring and Acceptance of Benefit by Hospital Officials: Opportunities and Limits of Third-Party Funding.- IX.a Poster: Hemophilia.- Experience with Recombinant Factor IX (Benefix) in Pediatrics.- Articular Cartilage Is More Susceptible to Blood-Induced Damage in Young Than in Old Age.- Chronic Liver Disease in Hemophilia Patients.- Human Immunodeficiency Virus-Negative “High-Risk Patients” with Hemophilia or Severe von Willebrand Disease Type 3: Coincidence or Genetics?.- Quality Management and Economic Aspects in Hemotherapy in the Federal Republic of Germany: Description of a Retrospective Cross-Sectional Multicenter Trial.- How Hemophiliacs View the Services Offered by “Bluter Betreuung Bayern e.V.”.- Alpha-Tocopherol — A Medication with Few Side Effects for Treating Pain in Patients with Hemarthrosis.- Neurosensorial Sequelae in Hemophilia.- IX.b Poster: Thrombophilia.- Effect of Vitamin Supplementation in Venous Thrombosis Patients with Hyperhomocysteinemia.- Therapy and Prophylaxis of the Thromboembolic Syndrome in Pregnancy and Post Delivery.- Is Factor V Leiden Associated with an Increased Risk for Fetal Loss?.- IX.c Poster: Molecular Biology.- Congenital Deficiency of Vitamin K Dependent Coagulation Factors in Two Families: Evidence for a Defective Vitamin K-Epoxide-Reductase Complex.- Twenty-Two Novel Mutations of Factor VII Gene in Factor VII Deficiency.- Prevalence of Common Mutations and Polymorphisms of the Genes of FII, FV, FVII, FXII, FXIII, MTHFR and ACE — Identified As Risk Factors for Venous and Arterial Thrombosis — in Germany and Different Ethnic Groups (Indians, Blacks) of Costa Rica.- Factor V Variants — FV Leiden, FV R2 Polymorphism (ex 13), FV DdeI Polymorphism (int 16) -— Risk Factors for Venous Thrombosis? Results of a Pilot Study.- Relation Between Prothrombin Mutation 20210 G?A, Prothrombin Time, Factor V Leiden and Prothrombin Level.- Localization and Characterization of Mutations within the Factor-VIII-Gene in a Cohort of 212 Patients with Hemophilia A.- Genomic Diagnosis of Hemophilia A in Hungarian Patients.- Indirect Genomic Diagnosis of Hungarian Hemophilia B Patients.- IX.d Poster: Pediatrics.- Relation of Cardiovascular Fitness, Hemostatic and Metabolic Risk Factors for Coronary Heart Disease in Obese Children and Adolescents.- Inverse Correlation Between Thyroid Function and Hemostatic Risk Factors for Coronary Heart Disease in Obese Children and Adolescents.- Heparin-Induced Thrombocytopenia Type II in Three Children and Anticoagulant Therapy with Org 10172 (Orgaran).- Heparin Concentration, Activated Clotting Time, and Markers of Coagulation Activation During Pediatrie Heart Catheterization.- Therapeutic Options in Immune Thrombocytopenic Purpura in Childhood.- Camps for Children and Young Adults with Hemophilia in Germany, Austria, and Switzerland.- Clinical Experience with the PFA-100 System in Children and Adolescents.- Endothelial Activation Markers in Health and Disease — Big Endothelin-1 and Endothelin-1 in Children.- IX.e Poster: Case Reports.- Dramatic Intra-Abdominal Bleeding — First Symptom of Hemophilia B in a Neonate.- Postoperative Bleeding in a Sufficiently Substituted Patient with Severe Hemophilia A: Successful Therapy with Administration of Recombinant Factor VIIa.- Continuous Infusion of Recombinant FIX (BeneFIX) During Herniotomy in an Infant.- Clinical Course of Intramuscular Bleeds in a Patient with Factor-XIII Deficiency.- Immunthrombocytopenia and Lupus Antibodies in a Patient with Hemophilia A.- Cerebral Sinus Thrombosis After Asparaginase Therapy.- Severe Neonatal Thrombosis in a Patient with Factor V Q:506 Mutation and the G20210A Prothrombin Mutation.- Elevated Lp(a) Level and Heterozygous Factor V Mutation FV 1691 AG in a 26-Year-Old Female with Ischemic Colitis.- Acquired Hemophilia in Women Postpartum.- IX.f Poster: Hemorrhagic Disorders.- Modulation of Antigens of Neutrophil Granulocytes by Extracorporal Apheresis.- Glycoprotein Ilb/IIIa Receptor Antagonist c7E3 Fab and Anticoagulants Show an Additive Effect on Thrombin-Induced Platelet Aggregation after High Coagulant Challenge In Vitro.- Between-Drug Comparison of the Effect of Ticlopidine and Acetylsalicylic Acid on Platelets in an In Vitro Circulation Model.- Rotablation Leads to Significant Platelet Activation: A Flow Cytometric Assessment.- Flow Cytometric Comparison of Platelet Activation During PTCA, Stent Implantation and Rotablation.- Analysis of Hemostatic Capacity before and after Extracorporal Platelet-Pheresis by the PFA-100 Test System.- Heparin Coating of Coronary Stents Increases Time Until Stent Occlusion Due to Delayed Platelet Activation in an In Vitro Circulating Model.- High-Speed Detection of Human Progenitor Cells (HPC) to Support the Timing of Aphereses.- Semi-Automated Flow Cytometry Can Help in Timing the Onset of Stem-Cell Leukapheresis.- IX.g Poster: Diagnostic Problems.- Current Topics of Official Batch Release: Determination of FXIII Activity in Fibrin Glues and FXIII Concentrates and Measurement of Heparin/AT Complexes in FVIII Products.- Comparison of BVDV and SFV Used as Models for Hepatitis C Virus in Virus Validation Studies.- Preoperative Coagulation Screening in Children Focused on PTT Elevation.- Resonance Thrombographic Analysis of Coagulation Status after Transfusion of Platelet Concentrates with Different Storage Times.

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Hematology.